The Harvoni tablet for HCV (kills the hepatitis C-virus) is to be sold at a special sale price (USD 400) in Mongolia from next August. The American “Gilead Sciences Company” is currently selling this product at USD 94,000 on the world market.  In this connection, the Ministry of Health and Sport and the “Gilead Sciences Company” signed a Memorandum of Understanding (MoU) earlier today. 

The Government of Mongolia (GoM) officially added this tablet to the “Medicine List” on 21st of May 2015. The “Gilead Sciences Company” will produce “Harvoni” for Mongolia quickly at the request of the GoM. Subsequently, the first supplies of the medicine will be delivered to Mongolian (priority) patients in August; and enough by November for the remainder-informed the “Gilead Sciences Company”.

Mongolian patients who are diagnosed Hepatitis C Virus (HCV) by specific examination, have the possibility to buy one course of treatment at MNT 742,800 and three months treatment at MNT 2, 228,400 from the official distributor the “Ombol Company” pharmacies.  

There are currently 200,000 HCV patients in Mongolia. Also, 52,000 of them suffer from chronic hepatitis and they require special treatment. Therefore, the Ministry of Health and Sport has decided to provide first consignment of the medicine to these 52,000 patients.

International experts have proven that Harvoni has no side effects.